Please login to the form below

Teva and Novartis settle patent lawsuit

Teva Pharmaceuticals will settle patent litigation with Novartis involving Teva's US generic version of antiviral medication Famvir

Teva Pharmaceuticals, US, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of the Novartis-developed antiviral medication Famvir (famciclovir).

The settlement includes all claims for patent infringement and damages.

Under the terms of the agreement, Israel-based Teva will make an undisclosed one-time payment to Novartis plus ongoing royalties on US sales of its product, which is used to treat herpes and shingles.

Teva is among the top 15 global pharmaceutical companies and is a leading generic pharmaceutical company. Teva launched the generic version of Famvir in September 2007.

16th February 2010

PME Digital Edition

Featured jobs

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Associate Medical Director: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Experienced Editor, London, Medical Communications: Competitive package

Account Manager, Healthcare Advertising: Salary TBC

Director Healthcare PR Communications: Salary TBC

Account Director: Negotiable

Senior Account Executive – Medical Communications: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Associate Medical Director: Highly Competitive

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Account Director – Global Healthcare PR: Salary TBC

Project / Account Manager (Medical Education): Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Scientific Director: Highly Competitive Salary &Benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Editorial Director – Medical Education: Neg

Director – Head of Public Affairs: Neg

Consultant Health Economics - London / Oxford: Negotiable

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Scientific Team Lead: Competitive Salary

Senior Systematic Review Analyst - Oxford: Negotiable

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe: Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...